Vaccination against murine gamma-herpesvirus infection.
The gamma-herpesviruses establish life-long latency in the host and are important human pathogens. T cells play a major role in controlling the initial acute infection and subsequently maintaining the virus in a quiescent state. However, the nature of the T-cell response to gamma-herpesvirus infection and the requirements for effective vaccination are poorly understood. The recent development of a murine gamma-herpesvirus (murine herpesvirus-68 [MHV-68]) has made it possible to analyze T-cell responses and test vaccination strategies in a small animal model. Intranasal infection with MHV-68 induces an acute infection in the lung and the subsequent establishment of long-term latency, which is associated with splenomegaly and an infectious mononucleosis-like syndrome. Here we review the T-cell response to different phases of the infection and the impact of vaccination against either lytic-cycle, or latency-associated T-cell epitopes.
Woodland
D L
DL
Trudeau Institute, Saranac Lake, New York 12983, USA.
Usherwood
E J
EJ
Liu
L
L
Flaño
E
E
Kim
I J
IJ
Blackman
M A
MA
D000818:Animals; D004195:Disease Models, Animal; D018142:Gammaherpesvirinae / Q000276:immunology* / Q000502:physiology; D006566:Herpesviridae Infections / Q000517:prevention & control*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination
D022283:Herpesvirus Vaccines